Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.45 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31714439 | 0.86 | HSD17B10 (0.51) | CYP1A2ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7658698 | 0.85 | CYP1A2 (0.55) | CYP1A2TDP1ALDH1A1MAPK1HIF1A | |
| SCHEMBL7782688 | 0.84 | MAPK1 (0.47) | ALDH1A1MAPK1TSHRSMN1; SMN2MEN1 | |
| SCHEMBL7784575 | 0.84 | CYP1A2 (0.58) | CYP1A2TDP1ALDH1A1MAPK1HIF1A | |
| SCHEMBL7784570 | 0.84 | CYP1A2 (0.58) | CYP1A2TDP1ALDH1A1MAPK1HIF1A | |
| SCHEMBL27961047 | 0.82 | CYP1A2 (0.68) | CYP1A2TDP1ALDH1A1MAPK1HIF1A | |
| SCHEMBL7783341 | 0.80 | CYP1A2 (0.60) | CYP1A2TDP1ALDH1A1MAPK1HIF1A | |
| SCHEMBL10890268 | 0.79 | CYP1A2 (0.64) | CYP1A2TDP1ALDH1A1MAPK1HIF1A | |
| SCHEMBL10891708 | 0.79 | CYP1A2 (0.64) | CYP1A2TDP1ALDH1A1MAPK1HIF1A | |
| SCHEMBL7783353 | 0.78 | ALDH1A1 (0.59) | ALDH1A1MAPK1HPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-0901501-B1 | NUCLEOSIDE DERIVATIVES WITH PHOTO-UNSTABLE PROTECTIVE GROUPS | PFLEIDERER WOLFGANG (DE) | 2001-10-17 | — | — | EP | disclosed |
| US-6153744-A | LIGHT-CONTROLLED SYNTHESIS OF OLIGONUCLEOTIDES ON A DNA CHIP | WOLFGANG PFLEIDERER (DE) | 2000-11-28 | — | — | US | disclosed |
| EP-0901501-A1 | NUCLEOSIDE DERIVATIVES WITH PHOTO-UNSTABLE PROTECTIVE GROUPS | Pfleiderer, Wolfgang (DE) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997044345-A1 | NUCLEOSIDE DERIVATIVES WITH PHOTO-UNSTABLE PROTECTIVE GROUPS | PFLEIDERER WOLFGANG (DE) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | CYP1A2 145/4885TDP1 4591/4885ALDH1A1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.